Literature DB >> 17646833

What are the consequences of the fourth case?

Christopher Baum.   

Abstract

Mesh：

Year:  2007        PMID： 17646833     DOI： 10.1038/sj.mt.6300263

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  7 in total

Review 1.  Targeted gene insertion for molecular medicine.

Authors:  Katrin Voigt; Zsuzsanna Izsvák; Zoltán Ivics
Journal:  J Mol Med (Berl)       Date:  2008-07-08       Impact factor: 4.599

2.  Efficient derivation of alveolar type II cells from embryonic stem cells for in vivo application.

Authors:  Blair Roszell; Mark J Mondrinos; Ariel Seaton; Donald M Simons; Sirma H Koutzaki; Guo-Hua Fong; Peter I Lelkes; Christine M Finck
Journal:  Tissue Eng Part A       Date:  2009-11       Impact factor: 3.845

3.  Neonatal intravenous injection of a gammaretroviral vector has a low incidence of tumor induction in mice.

Authors:  Mindy Tittiger; Xiucui Ma; Lingfei Xu; Katherine P Ponder
Journal:  Hum Gene Ther       Date:  2008-11       Impact factor: 5.695

4.  A large U3 deletion causes increased in vivo expression from a nonintegrating lentiviral vector.

Authors:  Matthew Bayer; Boris Kantor; Adam Cockrell; Hong Ma; Brian Zeithaml; Xiangping Li; Thomas McCown; Tal Kafri
Journal:  Mol Ther       Date:  2008-09-16       Impact factor: 11.454

5.  Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells.

Authors:  Elodie Robert-Richard; François Moreau-Gaudry; Magalie Lalanne; Isabelle Lamrissi-Garcia; Muriel Cario-André; Véronique Guyonnet-Dupérat; Laurence Taine; Cécile Ged; Hubert de Verneuil
Journal:  Am J Hum Genet       Date:  2008-01       Impact factor: 11.025

6.  Retroviral vector integration in post-transplant hematopoiesis in mice conditioned with either submyeloablative or ablative irradiation.

Authors:  M A Sadat; S Dirscherl; L Sastry; J Dantzer; N Pech; S Griffin; T Hawkins; Y Zhao; C N Barese; S Cross; A Orazi; C An; W S Goebel; M C Yoder; X Li; M Grez; K Cornetta; S D Mooney; M C Dinauer
Journal:  Gene Ther       Date:  2009-12       Impact factor: 5.250

7.  Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy.

Authors:  Gaetano Romano
Journal:  ISRN Oncol       Date:  2012-11-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.